Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Liabilities and Shareholders Equity (2019 - 2026)

Atea Pharmaceuticals' Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $267.1 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity fell 39.3% to $267.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Mar 2026, down 30.91% year-over-year, with the annual reading at $315.2 million for FY2025, 32.16% down from the prior year.
  • Liabilities and Shareholders Equity came in at $267.1 million for Q1 2026, down from $315.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $717.2 million in Q1 2022 to a low of $267.1 million in Q1 2026.
  • The 5-year median for Liabilities and Shareholders Equity is $553.0 million (2024), against an average of $529.9 million.
  • Year-over-year, Liabilities and Shareholders Equity decreased 9.84% in 2023 and then tumbled 39.3% in 2026.
  • Atea Pharmaceuticals' Liabilities and Shareholders Equity stood at $666.7 million in 2022, then fell by 10.76% to $595.0 million in 2023, then fell by 21.9% to $464.7 million in 2024, then crashed by 32.16% to $315.2 million in 2025, then dropped by 15.27% to $267.1 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Liabilities and Shareholders Equity are $267.1 million (Q1 2026), $315.2 million (Q4 2025), and $343.0 million (Q3 2025).